Impact of Chemoradiation on Prognosis in Stage IVB Cervical Cancer with Distant Lymphatic Metastasis
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Purpose The purpose of this study was to determine whether chemoradiation (CCR) is efficient for improving prognosis, compared with systemic chemotherapy (SC), in patients with stage IVB cervical cancer who have distant lymphatic metastasis. Materials and Methods Among 2,322 patients with cervical cancer between January 2000 and March 2010,43 patients (1.9%) had stage IVB disease. After exclusion of 19 patients due to insufficient data and hematogenous metastasis, 24 patients (1%) who received CCR (n=10) or SC (n=14) were enrolled. We compared tumor response, progression-free survival (PFS) and overall survival (OS), and disease recurrence between CCR and SC. Results Complete response rates were 60% and 0% after CCR and SC (p＜0.01). Grade 3 or 4 leukopenia was more common in patients treated with CCR (24.4% vs. 9.1%,p=0.03), whereas grade 3 or 4 neuropenia was more frequent in those treated with SC (28.4% vs. 11.1%, p=0.03). Development of grade 3 proctitis occurred as a late radiotherapy (RT)-related toxicity in only one patient (10%) treated with CCR. In addition,squamous cell carcinoma and CCR were favorable prognostic factors for improvement of PFS (adjusted hazard ratios [HRs], 0.17 and 0.12; 95% confidence intervals [CIs], 0.04 to 0.80 and 0.03 to 0.61), and only CCR was significant for improvement of OS (adjusted HR, 0.15; 95% CI, 0.02 to 0.90). However, no differences in the rate and pattern of disease recurrence were observed between CCR and SC. Conclusion CCR may be more effective than SC for improving survival, and can be regarded as a feasible method with some caution regarding late RT-related toxicity for treatment of stage IVB cervical cancer with distant lymphatic metastasis.
Abstract
Purpose The purpose of this study was to determine whether chemoradiation (CCR) is efficient for improving prognosis, compared with systemic chemotherapy (SC), in patients with stage IVB cervical cancer who have distant lymphatic metastasis. Materials and Methods Among 2,322 patients with cervical cancer between January 2000 and March 2010,43 patients (1.9%) had stage IVB disease. After exclusion of 19 patients due to insufficient data and hematogenous metastasis, 24 patients (1%) who received CCR (n=10) or SC (n=14) were enrolled. We compared tumor response, progression-free survival (PFS) and overall survival (OS), and disease recurrence between CCR and SC. Results Complete response rates were 60% and 0% after CCR and SC (p＜0.01). Grade 3 or 4 leukopenia was more common in patients treated with CCR (24.4% vs. 9.1%,p=0.03), whereas grade 3 or 4 neuropenia was more frequent in those treated with SC (28.4% vs. 11.1%, p=0.03). Development of grade 3 proctitis occurred as a late radiotherapy (RT)-related toxicity in only one patient (10%) treated with CCR. In addition,squamous cell carcinoma and CCR were favorable prognostic factors for improvement of PFS (adjusted hazard ratios [HRs], 0.17 and 0.12; 95% confidence intervals [CIs], 0.04 to 0.80 and 0.03 to 0.61), and only CCR was significant for improvement of OS (adjusted HR, 0.15; 95% CI, 0.02 to 0.90). However, no differences in the rate and pattern of disease recurrence were observed between CCR and SC. Conclusion CCR may be more effective than SC for improving survival, and can be regarded as a feasible method with some caution regarding late RT-related toxicity for treatment of stage IVB cervical cancer with distant lymphatic metastasis.
참고문헌 (20)
- Dong Hoon Suh, "Major clinical research advances in gynecologic cancer in 2011", Journal of Gynecologic Oncology, 23(1), pp.53~64 (2012), 대한부인종양학회
- ". Fort Washington"[URL]
- Pectasides D, "Chemotherapy for recurrent cervical cancer", Cancer Treat Rev, 34, pp.603~613 (2008)
- Heon Jong Yoo, "Pelvic exenteration for recurrent cervical cancer: ten-year experience at National Cancer Center in Korea", Journal of Gynecologic Oncology, 23(4), pp.242~250 (2012), 대한부인종양학회
- Moore DH, "Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study", J Clin Oncol, 22, pp.3113~3119 (2004)
- Monk BJ, "Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group Study", J Clin Oncol, 27, pp.4649~4655 (2009)
- Saito I, "A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group", Japan Clinical Oncology Group Study, 2010, pp.40, 90~93
- Kartalou M, "Mechanisms of resistance to cisplatin", Mutat Res, 478, pp.23~43 (2001)
- Hill BT, "Differing patterns of cross-resistance resulting from exposures to specific antitumour drugs or to radiation in vitro", Cytotechnology, 12, pp.265~288 (1993)
- Nishio S, "Analysis of the clinicopathological prognosis of stage IVb cervical carcinoma", Oncol Rep, 19, pp.497~503 (2008)
- Kim JY, "Curative chemoradiotherapy in patients with stage IVB cervical cancer presenting with paraortic and left supraclavicular lymph node metastases", Int J Radiat Oncol Biol Phys, 84, pp.741~747 (2012)
- Therasse P, "New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada", J Natl Cancer Inst, 92, pp.205~216 (2000)
- "Common Terminology Criteria for Adverse Events (CTCAE) v3.0"[URL]
- Sakurai H, "Analysis of recurrence of squamous cell carcinoma of the uterine cervix after definitive radiation therapy alone: patterns of recurrence, latent periods, and prognosis", Int J Radiat Oncol Biol Phys, 50, pp.1136~1144 (2001)
- Xiao ZF, "Influence of number of metastatic lymph nodes on survival of curative resected thoracic esophageal cancer patients and value of radiotherapy: report of 549 cases", Int J Radiat Oncol Biol Phys, 62, pp.82~90 (2005)
- 이석호, "Radiation therapy with chemotherapy for patients with cervical cancer and supraclavicular lymph node involvement", Journal of Gynecologic Oncology, 23(3), pp.159~167 (2012), 대한부인종양학회
- Kim HS, "Matched-case comparison for the efficacy of neoadjuvant chemotherapy before surgery in FIGO stage IB1-IIA cervical cancer", Gynecol Oncol, 119, pp.217~224 (2010)
- Jhingran A, "Potential advantages of intensity-modulated radiation therapy in gynecologic malignancies", Semin Radiat Oncol, 16, pp.144~151 (2006)
- Rose PG, "Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study", J Clin Oncol, 17, pp.2676~2680 (1999)
- Narayan K, "Patterns of failure and prognostic factor analyses in locally advanced cervical cancer patients staged by positron emission tomography and treated with curative intent", Int J Gynecol Cancer, 19, pp.912~918 (2009)